Methods and Products for Preventing and/or Treating Microorganism Infections (Def-Gapp)


A novel therapy for the treatment of bacterial biofilms


Chronic infections such as those exhibited in chronic wounds, pneumonia in cystic fibrosis patients, chronic otitis and chronic rhinosinusitis affect millions of people a year and many deaths can occur as a consequence. Whilst many targeted treatments of bacterial pathogenesis has focused on acute infection, this has been supplemented by chronic infections caused by bacteria growing in slime-enclosed, sessile aggregates called biofilms. These biofilms provide an extra level of protection and make treatment of biofilm-mediated disease more difficult with conventional antimicrobial agents, with resistance to antibiotics and evasion of host defenses. As such, there is a need for a more effective therapy to eradicate biofilms.

Targeting chronic rhinosinusitis, researchers at the University of Adelaide’s Department of Otolaryngology have identified an effective way of treating biofilms by targeting essential iron metabolism pathways in pathological bacteria. This is facilitated by the use of a chelating agent in concert with a heme mimetic, Gallium protoporhyrin IX. A strong antibacterial synergistic effect has been observed when these two agents are administered in combination to treat S. aureus biofilms.

In vivo expts (to come) 

Further efforts have been made to develop a single dose therapeutic formulation (further data required)


Commercial Applications

This technology will be of interest to operations in the fields of: anti-infectives, antibiotic resistance, biofilm treatment, chronic-rhinosinusitis.

Partnering Opportunities

Complementary to the expertise of our existing team or researchers, industry and development partners, we are pleased to consider expressions of interest and enquiries from additional relevant partners and/or prospective licensees.



Patent Information:
For Information, Contact:
JC Tan
The University of Adelaide